Biogen’s Tysabri (natalizumab, SC) Receives EC’s Marketing Authorization to Treat Relapsing-Remitting Multiple Sclerosis

  • by

Shots:

  • The EC’s approval is based on data from DELIVER and REFINE studies evaluating the efficacy, PK, and PD of Tysabri (300mg, SC, q4w) vs Tysabri (300mg, IV, q4w) in patients with RRMS
  • The results demonstrated that the Tysabri (SC) in both studies showed clinical benefits and well-characterized safety profile. The SC option expands the clinical settings while safety is consistent with IV formulation in other clinical studies and the post-marketing setting
  • Tysabri is the only high-efficacy MS therapy to offer two routes of administration options thus, providing flexibility to meet patients’ individual preferences and needs

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: The Business Journals

The post Biogen’s Tysabri (natalizumab, SC) Receives EC’s Marketing Authorization to Treat Relapsing-Remitting Multiple Sclerosis first appeared on PharmaShots.